Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRA-CER study of SCH 530348 added to standard care in acute coronary syndrome
2006-002809-31Phase 3Terminated
- Sponsor
- Schering AG
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing SCH 530348 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary efficacy endpoint. Started Nov 2007; status: terminated.
02
Drugs
vorapaxar
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2006-002809-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002809-31.